Company news

Brii Biosciences Limited news in 2023

Brii Biosciences Limited's news releases, calls and decks from 2023, newest first.

View company

Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination with PEG-IFNα for the Treatment of Chronic Hepatitis B

September 6, 2023

Brii Biosciences Provides Corporate Updates and Reports 2023 Interim Results

August 22, 2023

Brii Biosciences Broadens its Leadership in Hepatitis B with a Portfolio Now Addressing Disease's Burdens from Prevention to Cure

July 5, 2023

Brii Biosciences Provides Latest Clinical Development and Corporate Updates

July 5, 2023

Brii Biosciences Announces Entry into Definitive Agreements from Sale of its Equity Interest in Qpex Biopharma and Acquiring Exclusive Global Rights for BRII-693

June 25, 2023

Brii Biosciences Announces First Subject Dosed in Phase 1 Clinical Trial of BRII-297, Long-Acting Injectable for the Treatment of Anxiety and Depressive Disorders

May 30, 2023

Brii Bio Publishes 2022 Environmental, Social and Governance Report

April 27, 2023

Decks in 2023